Member Info for 42trader

Yes, that is the current amount able to be transported via pipeline which shows AMER is using less than half of the pipeline potential on the current pumps.

Not bad news but I do think this is more about saving his skin. 6500 production is good news but he's followed it by iterating overall production to be maintained from 5000-6000 for fy19, so no change there.
Good to hear third parties are going to be using the pipeline imminently. This could be the deal breaker for the company in years to come, providing a steady income. It will literally be a trickle to start with, with the pipeline able to carry between 9mbbl -18mbbl per day. This could be improved in time by upgrading the pumps and then allowing 50-70mbbl per day.
Currently there is a total of around 30mbbl/d being produced in the Putumayo region.

Chart wise, AMER is still in a downward movement, riding what was previously the top of the downward rend channel. Stoch has moved into over sold while RSI could still go lower.
http://www.chartupload.com/viewer.php?file=85794090721450233014.png

Position: While I do think the sp will drop lower and buying at 10p could well be a possibility, I think buying at this price will return good rewards in time. Worth a buy but hold some back for potentially lower price which may or may not come.

Holding up quite well after the pummelling the share didn’t get last week.
Though the company is far from perfect, maybe investors are seeing value here and a safe haven with all the brexit fears and the Chinese/US trade wars. Maybe investors see progress now that drax is going green. Or maybe it’s just the support holding the sp steady while the ftse drops.
I do hope the sp does drop to the next support though at around the 270s as I would like to buy more at a cheaper price but then, it would be nice to read a decent argument for a continual drop beyond the current price instead of just comments like “This is a really, really bad company”.

Huntsworth held an impressive Capital Markets Day yesterday that
comprised detailed presentations from Group Management followed by
senior leadership from Evoke (Marketing) and MEDiSTRAVA (Medical). We
view the key points as i) the global healthcare industry continues to grow
apace with medium/long-term expansion underpinned by demographics
and supported by R&D and innovation ii) Huntsworth is uniquely
positioned to serve this marketplace and continues to target 5-7% organic
revenue growth over the next 5yrs iii) margins are sustainable in Medical
(25%+) and Marketing (23%+) with Immersive set to grow from 14% to
17% over the next 3yrs iv) acquisitions to date have delivered excellent
returns - AboveNation (IRR 28%) and The Creative Engagement Group
(20%), while the group expects strong returns at Giant (13%+) and
Navience (14%+) and v) the Group continues to focus on cash generation
and a leverage target of 'around 1.5x'. We believe the CMD highlighted
the group's robust positioning and attractive fundamentals.
• Market dynamics. Global life expectancy is increasing, with people
aged 60+ set to double to 2bn+ by 2050. This provides a strong
backdrop for the global Healthcare industry, particularly for providers
of prescription drugs that treat chronic diseases. Huntsworth has the
infrastructure to capitalise on the growth in the healthcare marketplace.
• Marketing. We forecast Marketing will generate 42% of Group
revenues and 53% of pre-central cost EBITA in 2019. Reid Connolly
(CEO of Evoke) highlighted the positioning of the enlarged Evoke
Group to offer full-service media strategy, buying, planning and adtech.
After a pause in 2018, the AGM statement indicated Marketing is well
placed to return to growth in 2H19 and into 2020 due to improved new
business and greater collaboration across business units.
• Medical. We forecast Medical will account for 14% and 20% of 2019
Group revenues and pre-central cost EBITA, respectively. The
presentation by Elaine Ferguson (CEO of MEDiSTRAVA) illustrated the
involvement of Medical through the product life cycle. Medical growth
is underpinned by an increase in early phase engagements, rise in Real
World Evidence and growth in demand for consulting projects.

British Medical Journal suggested there should be a mandatory tax on the gambling industry to treat addiction in the UK.

Nice to see bod buying in at the support. Good chunky £50k

Says the shorter. I’ve got no qualm with shorting but really can’t stand people who ramp or dis a share. If you have some info worth saying, say it. But just saying it’s a bad share is pretty lame.
Congratulations. You are the first person I have filtered.

DRAX is looking under valued imo.
The conversion to become a green energy supplier has obviously come at a price.

NAV price of £4.49
P/E of 10.7 vs 11.9 industry average
PEG just 0.22
EPS growth of 92.8%

gla

Bought in today after watching for a while. Happy to add on further drops.
I see AlphaValue changed their rating to a buy (26/02/19) from sell (24/07/18).

"The group reported a 9% growth in adjusted EBITDA, translating the ramp-up of the wood pellet production activities (EBITDA up £15m), partly offset by technical issues in the Biomass generation division in Q1 and lower dark spreads in the UK.

The Power Generation division (93% of EBITDA) posted a £6m decline in EBITDA, to £232m, translating good underlying growth in the biomass generation business (fourth unit converted in August – 75% of generation from biomass) offset by weaker margins from coal generation due to higher carbon and coal prices. Consequently, electricity output was down 8%, to 18.3TWh. The group was able to reach a good overall biomass availability in Q2-Q4 which helped to offset a technical outage in Q1 (91% availability in 2018 vs. 79% in 2017).

The B2B Energy Supply business posted an EBITDA of £28m, broadly in line with last year (£29m). The group was able to increase its market share by 1% and its overall margin per meter and benefited from an additional month of Opus trading. This is slightly below target but remains a decent performance in such a competitive market.

The Wood Pellet business delivered strong growth in EBITDA (+£15m, to £21m) driven by increased output and a reduced cost per pellet (-10%). Total output was up 64%, to 1.35m tonnes, reflecting the postcommissioning ramp-up of Drax’ third pellet plan (LaSalle), which is now producing at full rate. Despite the 10% decrease in cost per tonne, biomass generation still has to rely on subsidies to be profitable. However, the group gave a few hints at what could be done to shift to a subsidy-free model. This includes reducing the cost further, notably thanks to the procurement of cheaper wood residues, new rail spur linking as well as a colocation agreement with a sawmill operator at the LaSalle facility.

At 31/12/2018, net debt/EBITDA was down 0.3x, to 1.3x, ahead of the 1.5x guidance although not including the impact stemming from the acquisition of Iberdrola’s generation assets as the deal was completed on 2 January 2019. Net debt/EBITDA should reach 2x by the end of 2019. "

670p target hit. If it can break above the resistance, then next target will be 750p where I'm looking to sell at.

After continual watching I held off buying here as I thought it may go lower. Bought to day in low 170's and got an alert set at 164p where I will add more, but not sure it will hit that low now.
Looking over sold on RSI and STOCH. Bounced off support this morning at 172p.
Approx. 60% under NAV.
Approx £320k of BOD buys in the last 6 months all above £2.
Special divi has been paid around may/june for the last 4 years. May see another soon?
P/E of just 8 almost half of industry average of 15.9.

Cenkos did do a report back on 26th March.

https://www.edisongroup.com/publication/atm-prudence-and-debt-management-actions/24054

Come on guys, be civil. At least the bloke is in aviation and is not a sailor.

I'm guessing the Henderson Group are selling out. There has to be a seller to free up this amount trades.
With hindsight, should of sold on the ex dividend day. But heyho, added today also, though holding some cash back as the sp has broken through previous low and support.

But are they buys? wouldn't it make sense that with the sp drop, the buys reported are actually sells?

When will production start? From briefly looking at a broker report they have figures starting from 2025.
From my experience, you can normally buy shares after a dilution 10-20% lower than the placing.
With a few years to go before production, I really don't see a rush to buy here, as there will surely be some hiccups along the way as nothing always goes to plan. Definitely a bottom draw share.

35p is tempting as there is some resistance there. Should hit 35p quite quickly imo. I think I may hold for 48p though where that is also the start of a gap to fill as well as the NAV price.

Been in and out of this over the years. Back in this morning though wary, so just a small stake.

Good to see the share price pass the resistance at 616, retrace and bounce of that resistance that should now become support. Next target price of 670p.